Your browser doesn't support javascript.
loading
Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells.
Amaya, Celina; Luo, Shihua; Baigorri, Julio; Baucells, Rogelio; Smith, Elizabeth R; Xu, Xiang-Xi.
Afiliação
  • Amaya C; Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Papanicolaou Building, Room 415 [M877], 1550 NW 10th Avenue, Miami, FL, 33136, USA.
  • Luo S; Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Papanicolaou Building, Room 415 [M877], 1550 NW 10th Avenue, Miami, FL, 33136, USA.
  • Baigorri J; HHMI High School Scholars Program, Department of Undergraduate Research and Community Outreach, University of Miami, Miami, FL, 33146, USA.
  • Baucells R; HHMI High School Scholars Program, Department of Undergraduate Research and Community Outreach, University of Miami, Miami, FL, 33146, USA.
  • Smith ER; Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
  • Xu XX; Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Papanicolaou Building, Room 415 [M877], 1550 NW 10th Avenue, Miami, FL, 33136, USA. xxu2@med.miami.edu.
BMC Cancer ; 21(1): 981, 2021 Sep 01.
Article em En | MEDLINE | ID: mdl-34470602
ABSTRACT

BACKGROUND:

Paclitaxel (Taxol) is a microtubule-stabilizing drug used to treat several solid tumors, including ovarian, breast, non-small cell lung, and pancreatic cancers. The current treatment of ovarian cancer is chemotherapy using paclitaxel in combination with carboplatin as a frontline agent, and paclitaxel is also used in salvage treatment as a second line drug with a dose intensive regimen following recurrence. More recently, a dose dense approach for paclitaxel has been used to treat metastatic breast cancer with success. Paclitaxel binds to beta tubulin with high affinity and stabilizes microtubule bundles. As a consequence of targeting microtubules, paclitaxel kills cancer cells through inhibition of mitosis, causing mitotic catastrophes, and by additional, not yet well defined non-mitotic mechanism(s).

RESULTS:

In exploring methods to modulate activity of paclitaxel in causing cancer cell death, we unexpectedly found that a brief exposure of paclitaxel-treated cells in culture to low intensity ultrasound waves prevented the paclitaxel-induced cytotoxicity and death of the cancer cells. The treatment with ultrasound shock waves was found to transiently disrupt the microtubule cytoskeleton and to eliminate paclitaxel-induced rigid microtubule bundles. When cellular microtubules were labelled with a fluorescent paclitaxel analog, exposure to ultrasound waves led to the disassembly of the labeled microtubules and localization of the signals to perinuclear compartments, which were determined to be lysosomes.

CONCLUSIONS:

We suggest that ultrasound disrupts the paclitaxel-induced rigid microtubule cytoskeleton, generating paclitaxel bound fragments that undergo degradation. A new microtubule network forms from tubulins that are not bound by paclitaxel. Hence, ultrasound shock waves are able to abolish paclitaxel impact on microtubules. Thus, our results demonstrate that a brief exposure to low intensity ultrasound can reduce and/or eliminate cytotoxicity associated with paclitaxel treatment of cancer cells in cultures.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias da Mama / Paclitaxel / Ondas Ultrassônicas / Microtúbulos / Mitose Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias da Mama / Paclitaxel / Ondas Ultrassônicas / Microtúbulos / Mitose Idioma: En Ano de publicação: 2021 Tipo de documento: Article